Conference on Q3 FY2025
(April 1, 2025 to December 31, 2025)
Financial Results

Toru Kimura, President and CEO

Sumitomo Pharma Co., Ltd.

January 30, 2026

Sumitomo Pharma
Innovation today, healthier tomorrows

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements and involve both known and unknown risks and uncertainties.

Accordingly, due to various subsequent factors, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and other products (including those under development) contained herein is not intended as advertising or as medical advice.

Financial Results for Q3 FY2025

Financial Results for Q3 FY2025 (Core Basis)

Performance exceeds expectations
Forecasts remain unchanged

Billions of JPY

	Q3YTD FY2024 Results	Q3YTD FY2025 Results	Change			FY2025	
			Value	FX impact	%	Oct. 31 forecasts	%
Revenue	293.2	**347.7**	54.6	(7.6)	18.6	429.0	81.1
Cost of sales	113.5	**145.1**	31.6	(2.1)	27.9	186.5	77.8
Gross profit	179.7	**202.6**	22.9	(5.5)	12.8	242.5	83.5
SG&A expenses	124.4	**116.4**	(8.0)	(2.2)	(6.4)	152.0	76.6
R&D expenses	35.4	**27.8**	(7.5)	(0.5)	(21.3)	44.0	63.2
Others (core basis)	1.6	**51.1**	49.5			50.5	
Core operating profit	21.5	**109.4**	87.9	(2.8)	408.5	97.0	112.8
Adjustment items (negative number indicates net expense)	(8.3)	**0.3**	8.6			1.0	
Operating profit	13.2	**109.8**	96.5		730.0	98.0	112.0
Finance income/costs	10.8	**(8.2)**	(19.0)			(12.0)	
Profit before taxes	24.0	**101.5**	77.5		322.6	86.0	118.1
Income tax expenses	2.8	**(6.1)**	(8.9)			(6.0)	
Net profit attributable to owners of the parent	21.2	**107.7**	86.5		407.5	92.0	117.0

- Revenue increased primarily due to the growth of ORGOVYX® and GEMTESA® and sales milestone revenue from ORGOVYX®
- SG&A expenses and R&D expenses decreased due to business structure improvements and realignment of the regenerative medicine and cell therapy business
- Others (core basis)
  FY2025: Gain on partial transfer of the Asian business +¥49.0B
- Adjustment items:
  FY2024: Business structure improvement expenses in Japan and North America

Average rates:
Q3 FY2024 Results : 1US$ = ¥152.64, 1RMB = ¥21.17
Q3 FY2025 Results : 1US$ = ¥148.71, 1RMB = ¥20.12
FY2025 forecasts : 1US$ = ¥145.00, 1RMB = ¥20.12

Period end rates:
As of the end of March 2025 : 1US$ = ¥149.53, 1RMB = ¥20.59
As of the end of Dec. 2025 : 1US$ = ¥156.53, 1RMB = ¥20.74

Revenue of Major Products in North America

	Q3YTD FY2024 Results	Q3YTD FY2025 Results	Change	Q3YTD FY2024 Results	Q3YTD FY2025 Results	Change			FY2025		
						Value	FX impact	%	Oct. 31 forecasts		JPY-basis Progress %
North America	Millions of USD			Billions of JPY					Millions of USD	Billions of JPY	
ORGOVYX®	379	**777**	398	57.8	**115.6**	57.8	(3.1)	99.9	1,020	147.9	78.1
MYFEMBREE®	66	**73**	7	10.1	**10.9**	0.8	(0.3)	8.4	85	12.3	88.6
GEMTESA®	283	**486**	203	43.2	**72.3**	29.1	(1.9)	67.5	588	85.3	84.8
RETHYMIC®	33	**30**	(3)	5.1	**4.6**	(0.5)	(0.1)	(10.5)	45	6.5	70.0
APTIOM®	200	**85**	(115)	30.5	**12.6**	(17.9)	(0.3)	(58.7)	85	12.3	102.2
Others	43	**44**	2	6.5	**6.6**	0.1	(0.2)	1.1	340	49.3	84.4
Export products/ One-time revenue, etc.*	172	**234**	62	26.2	**35.0**	8.8	(0.9)	33.4			
Total	1,175	**1,730**	555	179.4	**257.5**	78.1	(6.8)	43.6	2,163	313.6	82.1

- ORGOVYX® and GEMTESA® revenue increased significantly year-on-year
- APTIOM® revenue decreased due to loss of exclusivity
- Sales milestone revenue from ORGOVYX® has been recognized

* Major items included in Export products/One-time revenue, etc.

Q3YTD FY 2024 Results	Deferred revenue from the collaboration with Pfizer	$147M	Q3YTD FY 2025 Results	Deferred revenue from the collaboration with Pfizer	$66M
				Sales milestone revenue from ORGOVYX®	$100M

Average rates:
Q3 FY2024 Results : 1US$ = ¥152.64
Q3 FY2025 Results : 1US$ = ¥148.71
FY2025 forecasts : 1US$ = ¥145.00

FY2025 Q3 Financial Results Summary

ORGOVYX®

Plan for Q3 YTD FY2025	Actual for Q3 YTD FY2025	Year-over-year comparison
$742M	**$777M (Achievement 105%)**	**205%**

- Volume: Exceeded plan for Q3 YTD FY2025 due to higher-than- expected prescriptions and WHS inventory
- Price: In line with expectations

Quarterly Demand Trends* (number of bottles, estimation)



<Topics>

- Significant increase in New Patient Starts since Jan. 2025
  - Growth in Medicare patients due to the reduction of out-of-pocket caps
  - Increase in patients in Uro IOD and Academic/IDN channels by promoting product attributes
  - All-time-high New Patient Starts and volume in December

* *Source:* Internal calculation

FY2025 Q3 Financial Results Summary

MYFEMBREE®

Myfembree® (relugolix, estradiol, and norethindrone acetate) tablets 40 mg, 1 mg, 0.5 mg

Plan for Q3 YTD FY2025	Actual for Q3 YTD FY2025	Year-over-year comparison
$66M	**$73M (Achievement 110%)**	**111%**

- Volume：In line with expectations
- Price：In line with expectations

Quarterly Demand Trends* (number of bottles, estimation)



<Topics>

- Maintained sales volume even after termination of Pfizer collaboration
  - Improved operational efficiencies through reorganization of sales teams' structures along with GEMTESA® (Primary Care focus)
  - Maintained volume even under the shrinking GnRH market due to the termination of the majority of competitor promotion
  - Initiated online promotion of co-pay savings program

* Source: *Symphony Health, an ICON plc Company, Metys®, April 1, 2021, to December 31, 2025.*

FY2025 Q3 Financial Results Summary

GEMTESA®

Plan for Q3 YTD FY2025	Actual for Q3 YTD FY2025	Year-over-year comparison
$453M	**$486M (Achievement 107%)**	**172%**

- Volume：Delivered volume growth exceeding plan for Q3 YTD FY2025 amid continued expansion of the β3 market
- Price：Favorable payer mix

Quarterly Demand Trends*

（number of bottles, estimation）



＜Topics＞

- December volume reached all-time high, driven by deep penetration of product clinical advantages and an increase in Medicare patients due to the reduction in out-of-pocket cost caps
- NBRx growth outpaced competitors
- Expanded DTC and PR campaigns targeted to male patients by leveraging new indication for treating OAB in men on pharmacological therapy for BPH

** Source: Converted pill volume to number of bottles (30 tablets/bottle) based on information licensed from IQVIA: NPA for the period 4/1, 2021 to 12/31, 2025 reflecting estimates of real-world activity. All rights reserved.*

Revenue of Major Products in Japan

Billions of JPY

	Q3YTD FY2024 Results	Q3YTD FY2025 Results	Change		FY2025	
			Value	%	Oct. 31 forecasts	Progress %
Japan						
LATUDA®	10.2	**10.7**	0.4	4.2	13.5	78.9
TWYMEEG®	5.7	**7.9**	2.2	39.4	11.2	70.7
METGLUCO®	5.7	**5.7**	0.0	0.2	7.5	75.8
Equa®/EquMet®	20.9	**8.7**	(12.2)	(58.3)	9.0	97.1
LONASEN® Tape	3.6	**3.9**	0.3	8.2	5.0	77.4
AG products	8.8	**9.4**	0.6	6.6	11.6	80.6
Others	18.2	**17.7**	(0.5)	(2.8)	34.7	66.2
Export products/ One-time revenue, etc.	5.4	**5.3**	(0.1)	(2.0)		
Total	78.5	**69.2**	(9.3)	(11.8)	92.5	74.8

Note: Sales of each product are shown by invoice price

- TWYMEEG® revenue continued to grow
- Equa®/EquMet® revenue decreased due to loss of exclusivity (discontinued in Dec. 2025)

Segment Information (Core Basis)

Billions of JPY

		Japan	North America	Asia	Total
Q3YTD FY2025	Revenue	69.2	257.5	21.0	347.7
	Cost of sales	35.6	102.4	7.2	145.1
	Gross profit	33.7	155.1	13.8	202.6
	SG&A expenses	22.1	89.9	4.4	116.4
	Core segment profit	11.5	65.2	9.4	86.2
	R&D expenses				27.8
	Core operating profit				109.4
Q3YTD FY2024	Revenue	78.5	179.4	35.3	293.2
	Cost of sales	40.3	64.9	8.3	113.5
	Gross profit	38.2	114.4	27.0	179.7
	SG&A expenses	28.9	86.2	9.4	124.4
	Core segment profit	9.3	28.3	17.6	55.2
	R&D expenses				35.4
	Core operating profit				21.5
Change	Revenue	(9.3)	78.1	(14.3)	54.6
	SG&A expenses	(6.7)	3.7	(5.0)	(8.0)
	Core segment profit	2.2	36.9	(8.2)	30.9
	R&D expenses				(7.5)
	Core operating profit				87.9

Japan

- Despite the decline of gross profit due to lower revenue, core segment profit increased due to SG&A expense reduction

North America

- Core segment profit increased significantly due to revenue-driven growth in gross profit

Asia

- Core segment profit decreased due to the partial transfer of the Asian business

Research and Development

Research and Development

Development Pipeline (as of January 30, 2026)

Area	Generic name/Product code	Mechanism of action, etc.	Planned indication(s)	Development stage
Psychiatry & Neurology	DSP-0038	Serotonin 5-HT_{2A} receptor antagonist and serotonin 5-HT_{1A} receptor agonist	Alzheimer's disease psychosis	Phase 1
	DSP-0187*	Selective orexin 2 receptor agonist	Narcolepsy	Phase 1
	DSP-3456	Metabotropic glutamate receptor 2/3 negative allosteric modulator (mGluR2/3 NAM)	Treatment resistant depression	Phase 1
	DSP-0378	Gamma-aminobutyric acid (GABA) A receptor positive allosteric modulator	Progressive Myoclonic Epilepsy Developmental Epileptic Encephalopathy	Phase 1
	DSP-2342	Serotonin 5-HT_{2A} and 5-HT_7 receptor antagonist	To be determined	Phase 1
	CT1-DAP001/DSP-1083 (Japan)	Allogeneic iPS [induced pluripotent stem] cell-derived dopaminergic neural progenitor cells	Parkinson's disease/Investigator-initiated study	MAA submitted in August 2025
	CT1-DAP001/DSP-1083 (U.S.)	Allogeneic iPS cell-derived dopaminergic neural progenitor cells	Parkinson's disease/Investigator-initiated study, Company- sponsored clinical study	Phase 1/2
	HLCR011(Japan)	Allogeneic iPS cell-derived retinal pigment epithelial cells	Retinal pigment epithelium tear	Phase 1/2
	DSP-3077(U.S.)	Allogeneic iPS cell-derived retinal sheet	Retinitis pigmentosa	Phase 1/2
Oncology	enzomenib/DSP-5336	Selective menin inhibitor	Acute leukemia	Phase 2
	nuvisertib/TP-3654	PIM1 kinase inhibitor	Myelofibrosis	Phase 1/2
	SMP-3124	CHK1 inhibitor	Solid tumors	Phase 1/2
	DSP-0390	EBP inhibitor	Glioblastoma	Phase 1
Others	KSP-1007	β-lactamase inhibitor	Complicated urinary tract and intraabdominal infections, Hospital-acquired bacterial pneumonia	Phase 1
	fH1/DSP-0546LP	Split, Adjuvanted vaccine	Influenza virus prophylaxis	Phase 1

*Development rights: Japan, China, and certain Asian countries

Sumitomo Pharma

Major Topics in Clinical Development

Psychiatry & Neurology (Regenerative medicine/cell therapy)

Allogeneic iPS cell-derived dopaminergic neural progenitor cells (U.S., Japan) (collaboration with RACTHERA)

- Parkinson's disease

In December 2025, designated as an Orphan Regenerative Medical Product from the Ministry of Health, Labour and Welfare (MHLW), Japan

(Significance of this designation)
This designation allows us to fully leverage regulatory benefits, such as priority review, during the marketing authorization application process and an extended regulatory exclusivity period of up to 10 years following approval.

Oncology

enzomenib (DSP-5336) (U.S., Japan)

- In December 2025, presented the latest monotherapy data and combination data with venetoclax/azacitidine at the American Society of Hematology (ASH) 2025 Annual Meeting (see page 13-14 for details)

nuvisertib (TP-3654) (U.S., Japan)

- In December 2025, presented combination data with momelotinib at the ASH 2025 Annual Meeting (see page 15 for details)

Oral presentation data at ASH 2025 Annual Meeting
Data cut-off: October 4, 2025

Enzomenib Monotherapy for Relapsed/Refractory Acute Leukemia

KMT2A rearrangement (recommended dose: 300 mg BID / n = 15)

- ✓ **Currently conducting the confirmatory part of the study at the recommended dose of 300 mg BID for relapsed/refractory acute leukemia with KMT2A rearrangement. Based on the results of the confirmatory part, we plan to submit marketing authorization applications in Japan and the U.S.**

【Efficacy】

- ✓ **CR+CRh rate at the recommended dose of 300 mg BID in patients with acute leukemia harboring KMT2A rearrangement: 40.0%**
- ✓ **Duration of CR or CRh: 12.5 months; median overall survival: 11.8 months**

	300mg BID n = 15
Overall Response Rate (CR/CRh/CRi/MLFS)	73.3%
Composite CR rate (CR/CRh/CRi)	60%
CR+CRh rate	40%

NPM1 mutation（200 - 400 mg BID / n = 25）

- ✓ **Currently evaluating the recommended dose in the confirmatory part of the study for relapsed/refractory acute myeloid leukemia with NPM1 mutation**

【Efficacy】

- ✓ **CR+CRh rate at 200 mg BID to 400 mg BID in patients with acute myeloid leukemia harboring NPM1 mutation: 37.5–50%**

	200mg BID n = 10	300mg BID n = 7	400mg BID n = 8
Overall Response Rate (CR/CRh/CRi/MLFS)	60%	57.1%	37.5%
Composite CR rate (CR/CRh/CRi)	50%	42.9%	37.5%
CR+CRh rate	50%	42.9%	37.5%

【Safety】

- ✓ **No dose-limiting toxicities (DLTs) or treatment-related deaths associated with enzomenib have been observed**
- ✓ **Differentiation syndrome occurred in 12.9% of patients (Grade ≥3: 7.8%), and QT prolongation in 9.5% (Grade 3: 2.6%), but no cases resulted in death or discontinuation of enzomenib**

CR: Complete Remission, CRh: Complete Remission with Partial Hematologic Recovery, CRi: Complete Remission with Incomplete Blood Count Recovery, MLFS: Morphologic Leukemia-Free State

Oral presentation data at ASH 2025 Annual Meeting
Data cut-off: October 4, 2025

Enzomenib Combination Therapy with Ven/Aza for Relapsed/Refractory Acute Myeloid Leukemia

- ✓ **In combination therapy with venetoclax/azacitidine (Ven/Aza) for relapsed/refractory AML with KMT2A rearrangement or NPM1 mutation, no dose-limiting toxicities were observed, and encouraging clinical activity was demonstrated**
- ✓ **Plan to initiate a combination cohort with Ven/Aza for newly diagnosed AML**

【Efficacy】

- ✓ **In the overall population receiving combination therapy with venetoclax/azacitidine for relapsed/refractory AML, the objective response rate (ORR) was 77%, and the composite remission rate (CRc) was 50%**
- ✓ **Among patients without prior menin inhibitor treatment, the objective response rate (ORR) was 85%, and the composite remission rate (CRc) was 62%**

* n = overall population / population without prior menin inhibitor treatment

		140mg BID + Ven/Aza 100mg n = 4 / n = 3	200mg BID + Ven/Aza 100mg n = 6 / n = 3	300mg BID + Ven/Aza 100mg n = 8 / n = 4	300mg BID + Ven/Aza 50-100mg n = 8 / n = 3	Total n = 26 / n = 13
		Without azole co-administration			azole co-administration	
Overall population	Overall Response Rate (CR/CRh/CRi/MLFS)	100%	83%	62.5%	80%	77%
	Composite CR rate (CR/CRh/CRi)	50%	50%	50%	50%	50%
Population within the overall group without prior menin inhibitor treatment	Overall Response Rate (CR/CRh/CRi/MLFS)	100%	100%	75%	67%	85%
	Composite CR rate (CR/CRh/CRi)	66.7%	66.7%	75%	33%	62%

【Safety】

- ✓ **No dose-limiting toxicities (DLTs) or treatment-related deaths associated with enzomenib have been observed. Differentiation syndrome occurred in 10.0% of patients (Grade ≥3: 0%), and QT prolongation in 10.0% (Grade ≥3: 0%), but no cases resulted in death or discontinuation of enzomenib**

CR: Complete Remission, CRh: Complete Remission with Partial Hematologic Recovery, CRi: Complete Remission with Incomplete Blood Count Recovery, MLFS: Morphologic Leukemia-Free State

Oral presentation data at ASH 2025 Annual Meeting
Data cut-off: October 15, 2025

Nuvisertib Combination Therapy with Momelotinib for Relapsed/Refractory Myelofibrosis

✓ **Obtained efficacy and safety data supporting the development of nuvisertib in combination therapy with momelotinib for myelofibrosis**

【Efficacy】
✓ **Improvements in total symptom score (TSS) and spleen volume, both key efficacy measures, were observed in high-risk patients, including those who had not responded adequately to prior JAK inhibitor therapy or those with anemia**
✓ **Improvements in TSS were observed early in treatment and appeared to be sustained over time, while hemoglobin levels remained stable throughout combination therapy with momelotinib**

Percentage of patients with ≥25% improvement in spleen volume

At any time point: 50%
At Week 24: 50%



*Efficacy-evaluable patients (those who completed ≥24 weeks or discontinued due to adverse events or disease progression)

Rapid and sustained improvement in TSS



Hemoglobin Improvement



・Hemoglobin improvement of ≥1.5 g/dL without transfusion for at least 12 weeks

・For transfusion-dependent patients: ≥50% reduction in transfusion frequency; for transfusion-independent patients: hemoglobin improvement of ≥1.0 g/dL without transfusion for at least 12 weeks

【Safety】
✓ **Hemoglobin levels and platelet counts remained stable even with the combination therapy of nuvisertib and momelotinib**
✓ **The discontinuation rate through Week 24 (28%) was comparable to that reported in the Phase 3 study of momelotinib as a single agent (28%), suggesting the potential feasibility of long-term combination therapy with momelotinib**

Appendix

＜Contents＞

P.17	Q3FY2025	Financial Results for Q3 FY2025 (Full Basis)
P.18	Q3FY2025	Financial Position and Cash Flow
P.19	Q3FY2025	Prescription Trends of GEMTESA®
P.20	R&D	Main Events/Targets for FY2025
P.21	R&D	Product Launch Target
P.22	R&D	Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (RACTHERA Co., Ltd.)

Financial Results for Q3 FY2025 (Full Basis)

Billions of JPY

	Q3YTD FY2024 Results	Q3YTD FY2025 Results	Change	
			Value	%
Revenue	293.2	347.7	54.6	18.6
Cost of sales	113.8	145.1	31.4	27.6
Gross profit	179.4	202.6	23.2	12.9
SG&A expenses	131.0	119.5	(11.5)	(8.8)
R&D expenses	36.7	27.9	(8.9)	(24.1)
Other operating income and expenses	1.6	54.5	52.9	
Operating profit	13.2	109.8	96.5	730.0
Finance income and costs	10.8	(8.2)	(19.0)	
Profit before taxes	24.0	101.5	77.5	322.6
Income tax expenses	2.8	(6.1)	(8.9)	
Net profit attributable to owners of the parent	21.2	107.7	86.5	407.5

Financial Position and Cash Flow

Billions of JPY

B / S	As of March 2025	As of Dec. 2025	Change
Assets	742.6	815.5	72.9
Other non-current assets	28.2	58.3	30.1
Trade and other receivables	74.8	132.8	57.9
Assets held for sale	30.4	0.0	(30.4)
Liabilities	573.1	526.6	(46.5)
Bonds and borrowings	305.4	259.0	(46.5)
Deferred tax liabilities	26.6	14.7	(11.9)
Provisions	72.0	89.5	17.5
Liabilities directly associated with assets held for sale	3.5	0.0	(3.5)
Equity	169.5	288.9	119.5
Attributable to owners of the parent	169.5	288.9	119.5
(Ratio of equity attributable to owners of the parent to total assets)	22.8%	35.4%	

C / F	Q3 FY2024	Q3 FY2025	Change
Operating CF	5.5	42.3	36.8
Investment CF	97.4	24.4	(73.1)
Financial CF	(45.3)	(48.7)	(3.4)
Cash and cash equivalents at beginning of year	29.0	36.3	7.2
Cash and cash equivalents at end of period	85.4	57.3	(28.1)

- Increase in investments accounted for using the equity method
- Increase in accounts receivable due to sales growth, etc.
- Repayment of short-term borrowings, etc.
- Reversal of deferred tax liabilities due to assignment of intangible assets within our group
- Increase in provisions due to sales growth, etc.
- FY24: Sales of investment securities
  FY25: Proceeds from loss of control of subsidiaries
- FY24: Repayment of long-term borrowings
  FY25: Repayment of short-term borrowings, etc.

Appendix (Financial Results for Q3 FY2025)

Prescription Trends of GEMTESA®

- Despite the launch of Mirabegron generics in Apr. 2024, the total number of GEMTESA® prescriptions and new prescriptions continued to increase. However, since Jan. 2025, there was a slight decline due to changes in Medicare Part D coverage and other factors. Following this temporary trend, prescriptions have started to grow again and TRx has now reached an all-time high

TRx in β-3 Market



NBRx in β-3 Market



Source: Based on information licensed from IQVIA: NPA for the period 4/1, 2022 to 12/31, 2025 reflecting estimates of real-world activity. All rights reserved.

Main Events / Targets for FY2025 (as of January 30, 2026)

Psychiatry & Neurology	☐ Allogeneic iPS cell-derived products (Parkinson's disease): Obtain approval in Japan ⇒MAA submitted (Aug. 2025) ☐ Allogeneic iPS cell-derived products (Parkinson's disease): Advance Phase 1/2 study in the U.S. ☐ Allogeneic iPS cell-derived products (Retinal pigment epithelium tear): Start the randomized portion of the Phase 1/2 study in Japan ☐ Allogeneic iPS cell-derived products (Retinitis pigmentosa): Achieve clinical administration in the U.S.
Oncology	☐ enzomenib (DSP-5336): Completion of patient enrollment for Phase 2 study ☐ nuvisertib (TP-3654): Advance Phase 1/2 study (monotherapy or in combination with JAK inhibitors) ☐ SMP-3124: Advance Phase 1/2 study ☐ Advance early Phase studies of early stage compounds
Others	☐ Advance Phase 1 studies of universal influenza vaccine ☐ Advance early Phase studies of early stage compounds

Appendix (Research and Development)

Product Launch Target (as of January 30, 2026)



* Relapsed or refractory acute leukemia with KMT2A rearrangement or acute myeloid leukemia with NPM1 mutation

Appendix (Research and Development)

Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (RACTHERA Co., Ltd.) (as of January 30, 2026)

Brand name/Cell type Product code	Indications	JP/ US	Pre-clinical	Clinical research	Phase 1/2	Phase 3	Approval application	Approval→ Launch
RETHYMIC®	Congenital athymia	US						●
Dopaminergic neural progenitor cells (Allo iPS cell-derived) CT1-DAP001/DSP-1083	Parkinson's disease	JP US			●4 ●5		●1	Aiming to obtain approval in FY 2025
Retinal pigment epithelial cells (Allo iPS cell-derived) HLCR011	Retinal pigment epithelium tear	JP			●5			
Retinal sheet (3D retinal tissue) (Allo iPS cell-derived) DSP-3077	Retinitis pigmentosa	JP US		●2	●5			
Neural progenitor cells (Allo iPS cell-derived)	Spinal cord injury	JP US		●3				
Nephron progenitor cells (organ) (Auto/ Allo iPS cell-based induced)	Kidney failure	JP/ US	●					

1. Kyoto University Hospital 2. Kobe City Eye Hospital 3. Keio University Hospital
4. University of California San Diego School of Medicine 5. Company-sponsored clinical study


Sumitomo Pharma
Innovation today, healthier tomorrows